Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours

Geert Spierenburg; Peter Grimison; Christine Chevreau; Silvia Stacchiotti; Sophie Piperno‐Neumann; Axel Le Cesne; Virginia Ferraresi; Antoîne Italiano; Florence Duffaud; Nicolas Penel; Séverine Metzger; Sylvie Chabaud; L. van der Heijden; David Pérol; Michiel A. J. van de Sande; Jean Yves Blay; Hans Gelderblom

doi:10.1016/j.ejca.2022.06.028

Related publications

Article2020

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)

Mehdi Brahmi, Philippe A. Cassier, Armelle Dufresne, Sylvie Chabaud, Marie Karanian, Alexandra Meurgey, Amine Bouhamama, F. Gouin, Gualter Vaz, Jérôme Garret, Marie‐Pierre Sunyach, Aurélien Dupré, Perrine Marec‐Bérard, Nadège Corradini, David Pérol, Isabelle Ray‐Coquard, Jean Yves Blay

Article2025

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Andrew J. Wagner, William D. Tap, Sebastian Bauer, Jean Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W. Ryan, Charles Peterfy, John H. Healey, Michiel A. J. van de Sande, Meng Qian, Dale E. Shuster, Abdul Waheed Rajper, Xin Ye, Kristen M. Tecson, Margaret Wooddell, Silvia Stacchiotti

Article2025

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

Jean Yves Blay, Q. Devin, Maud Toulmonde, Armelle Dufresne, Nicolas Penel, Antoine Adenis, María Rios, François Bertucci, Florence Duffaud, Nelly Firmin, Thomas Valentin, Emmanuelle Bompas, Olivier Collard, Marc Pracht, Alice Hervieu, Benjamin Verret, Isabelle Ray‐Coquard, P. Cassier, Clémence Hénon, David Pérol, A. Italiano, Sylvie Chabaud,

Letter2021

Long-term follow-up of recovered patients with COVID-19

Monica Cortinovis, Norberto Perico, Giuseppe Remuzzi

Article2025

2691MO Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib: Exploratory long-term follow-up of the BFR14 trial

Q. Devin, A. Le Cesne, Jean Yves Blay

Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours

Discussion(0)

Related publications

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

Long-term follow-up of recovered patients with COVID-19

2691MO Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib: Exploratory long-term follow-up of the BFR14 trial